Leonardo M. Fabbri
University of Ferrara
579 Papers
7.1K Citations
Leonardo M. Fabbri is an academic researcher from University of Ferrara. The author has contributed to research in topics: COPD & Medicine. The author has an hindex of 109, co-authored 566 publications. Previous affiliations of Leonardo M. Fabbri include Imperial College London & University of California, San Francisco.
Chat about Author
Papers
Comparative efficacy of once-daily ciclesonide and budesonide in the treatment of persistent asthma.
Boulet Lp,Anton Drollmann,P. Magyar,M. Timar,A. Knight,Renate Engelstätter,Leonardo M. Fabbri +6 more
TL;DR: Ciclesonide 320 microg once daily by HFA-MDI without a spacer was at least as effective as budesonide 320 microscopic once daily in persistent asthma.
51
Postallergen inhaled budesonide reduces late asthmatic response and inhibits the associated increase of airway responsiveness to methacholine in asthmatics.
P.L. Paggiaro,Fl Dente,M. C. Morelli,L Bancalari,A Di Franco,D Giannini,Barbara Vagaggini,Elena Bacci,Leonardo M. Fabbri,Carlo Giuntini +9 more
TL;DR: It is suggested that inhaled budesonide may not only prevent but also reduce the late asthmatic response induced by allergen and that it might also be considered in the treatment of exacerbation of asthma.
50
Effect of roflumilast in patients with severe COPD and a history of hospitalisation.
TL;DR: Roflumilast provides greater therapeutic benefit in severe COPD patients with a hospitalisation in the prior year http://ow.ly/lzWy30bNBd4 .
50
Helicobacter pylori and chronic bronchitis
Michele Caselli,E Zaffoni,M. Ruina,S. Sartori,Lucio Trevisani,Adalberto Ciaccia,Vittorio Alvisi,Leonardo M. Fabbri,Alberto Papi +8 more
TL;DR: H. pylori infection seems to increase the risk of developing of chronic bronchitis, and an important step in this field will be to evaluate the possible change in the clinical conditions after successful eradication therapy in H.pylori-positive patients with chronic bronachitis.
49
Does roflumilast decrease exacerbations in severe COPD patients not controlled by inhaled combination therapy? The REACT study protocol.
Peter M.A. Calverley,Fernando J. Martinez,Leonardo M. Fabbri,Udo-Michael Goehring,Klaus F. Rabe +4 more
TL;DR: It is hypothesized that because roflumilast (a phosphodiesterase-4 inhibitor) has a different mode of action to bronchodilators and inhaled corticosteroids, it may provide additional benefits when added to these treatments in frequent exacerbators.
48